AU2006214105A1 - Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin - Google Patents

Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin Download PDF

Info

Publication number
AU2006214105A1
AU2006214105A1 AU2006214105A AU2006214105A AU2006214105A1 AU 2006214105 A1 AU2006214105 A1 AU 2006214105A1 AU 2006214105 A AU2006214105 A AU 2006214105A AU 2006214105 A AU2006214105 A AU 2006214105A AU 2006214105 A1 AU2006214105 A1 AU 2006214105A1
Authority
AU
Australia
Prior art keywords
cyr61
cancer
antibody
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006214105A
Other languages
English (en)
Inventor
Marsha A. Moses
Bo Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of AU2006214105A1 publication Critical patent/AU2006214105A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AU2006214105A 2005-02-18 2006-02-17 Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin Abandoned AU2006214105A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65411105P 2005-02-18 2005-02-18
US60/654,111 2005-02-18
PCT/US2006/005812 WO2006089212A2 (en) 2005-02-18 2006-02-17 Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin

Publications (1)

Publication Number Publication Date
AU2006214105A1 true AU2006214105A1 (en) 2006-08-24

Family

ID=36917123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006214105A Abandoned AU2006214105A1 (en) 2005-02-18 2006-02-17 Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin

Country Status (7)

Country Link
US (4) US7858324B2 (cg-RX-API-DMAC7.html)
EP (1) EP1849002A4 (cg-RX-API-DMAC7.html)
JP (1) JP5006802B2 (cg-RX-API-DMAC7.html)
CN (1) CN101120252A (cg-RX-API-DMAC7.html)
AU (1) AU2006214105A1 (cg-RX-API-DMAC7.html)
CA (1) CA2598217A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006089212A2 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
WO2006089212A2 (en) * 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
WO2007081385A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2007133710A2 (en) 2006-05-11 2007-11-22 Raindance Technologies, Inc. Microfluidic devices and methods of use thereof
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US9416192B2 (en) 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
ES2471379T3 (es) * 2008-08-05 2014-06-26 Toray Industries, Inc. Método para detectar el cáncer
CN101747435B (zh) * 2008-12-18 2013-06-19 上海市免疫学研究所 一种中和cyr61的单克隆抗体(杂交瘤)及其应用
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2273272A1 (en) 2009-07-06 2011-01-12 Stichting Katholieke Universiteit Method for predicting the outcome of chemotherapy in ovarian cancer
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
ES2583627T3 (es) 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
AU2011211698B2 (en) 2010-02-04 2015-07-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
PT2532367T (pt) 2010-02-04 2018-11-09 Toray Industries Agente farmacêutico para o tratamento e/ou prevenção do cancro
BR112012019098B8 (pt) 2010-02-04 2021-08-17 Toray Industries anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP2622103B2 (en) 2010-09-30 2022-11-16 Bio-Rad Laboratories, Inc. Sandwich assays in droplets
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
EP3736281A1 (en) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US9556470B2 (en) 2011-06-02 2017-01-31 Raindance Technologies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2012174498A2 (en) * 2011-06-16 2012-12-20 Pitari Giovanni M Biomarkers for epithelial cancer diagnosis and treatment
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013018894A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
JP6015448B2 (ja) 2011-08-04 2016-10-26 東レ株式会社 癌の治療及び／又は予防用医薬組成物
ES2609859T3 (es) 2011-08-04 2017-04-24 Toray Industries, Inc. Composición de fármaco para el tratamiento y/o la prevención del cáncer
MX351414B (es) 2011-08-04 2017-10-13 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
WO2013018883A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP3495817B1 (en) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molecular diagnostic screening assay
WO2013125640A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2013125636A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014021099A2 (pt) 2012-02-21 2020-12-01 Toray Industries, Inc anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo
RU2631804C2 (ru) 2012-02-21 2017-09-26 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения или профилактики рака
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
MX357965B (es) 2012-03-30 2018-08-01 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
KR102056654B1 (ko) 2012-07-19 2019-12-17 도레이 카부시키가이샤 암의 검출 방법
MX358772B (es) 2012-07-19 2018-09-04 Toray Industries Metodo para detectar cancer.
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
PL3031826T3 (pl) 2013-08-09 2019-03-29 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
CN107422125A (zh) * 2016-05-23 2017-12-01 中国医学科学院肿瘤医院 与肌层浸润性膀胱癌相关的尿液蛋白质标志物
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
CN108752454B (zh) * 2018-06-19 2021-07-20 中山大学孙逸仙纪念医院 一种人CYR61蛋白Ser188位点磷酸化抗原、抗体及其制备方法和应用
CN111426835A (zh) * 2019-01-10 2020-07-17 北京师范大学 肝转移癌相关的尿液蛋白标记物的筛选及其用途
CN113777315A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液泛素样蛋白isg15及其多肽片段在烧伤中的应用
CN112147337B (zh) * 2020-08-19 2024-05-28 德赛诊断系统(上海)有限公司 一种富含半胱氨酸蛋白61高敏化学发光检测试剂盒及其制备和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU2001271365A1 (en) 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
EP1322778A4 (en) * 2000-09-29 2005-06-15 Wyeth Corp APPLICATION OF CYR61 IN THE TREATMENT AND DIAGNOSIS OF HUMAN UTERUS MYOMENIC
US20040086504A1 (en) * 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
EP1434993B1 (en) 2001-09-18 2013-04-24 Fibrogen, Inc. Methods of assaying connective tissue growth factor
JP2003177126A (ja) * 2001-12-13 2003-06-27 Kenichi Katsube Ｃｃｎファミリー蛋白質活性制御剤のスクリーニング方法
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
EP2083270B1 (en) * 2003-03-27 2019-06-12 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
JP2004315480A (ja) * 2003-04-21 2004-11-11 Yoshiyuki Kakehi 前立腺疾患治療用医薬組成物
WO2006089212A2 (en) * 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin

Also Published As

Publication number Publication date
WO2006089212A3 (en) 2007-01-11
US20110189700A1 (en) 2011-08-04
CA2598217A1 (en) 2006-08-24
US20170205419A1 (en) 2017-07-20
EP1849002A4 (en) 2008-08-20
CN101120252A (zh) 2008-02-06
US20080286811A1 (en) 2008-11-20
WO2006089212A2 (en) 2006-08-24
EP1849002A2 (en) 2007-10-31
US20190154693A1 (en) 2019-05-23
JP5006802B2 (ja) 2012-08-22
US7858324B2 (en) 2010-12-28
JP2008530582A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
US7858324B2 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
US20190361028A1 (en) Free ngal as a biomarker for cancer
US8685659B2 (en) Method for diagnosis and prognosis of epithelial cancers
US20100209944A1 (en) Adamts-7 as a biomarker for cancers of epithelial origin
CA2552882C (en) Methods for diagnosis and prognosis of cancers of epithelial origin
WO2009017475A1 (en) Methods for diagnosis and prognosis of epithelial cancers

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period